Search | Clinical Trials Finder

Conditions: Common Wart
Interventions: A-101 Topical Solution, A-101 Vehicle Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Rogers, Arkansas • San Diego, California + 13 more

Conditions: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical vehicle solution; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more

Conditions: Common Wart
Interventions: A-101, vehicle; Drug · Other
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 24
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 21 more

Conditions: Seborrheic Keratosis
Interventions: A-101; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Portland, Oregon • Fort Washington, Pennsylvania • Austin, Texas + 1 more

Conditions: Onychomycosis
Interventions: ME1111 solution, Vehicle Solution; Drug
Lead sponsor: Meiji Seika Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 2
States / cities: Austin, Texas • College Station, Texas

Conditions: Dry Eye Syndrome
Interventions: TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Interventions: TP-03, TP-03 Vehicle; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more

Conditions: Dry Eye Disease
Interventions: 0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo; Drug
Lead sponsor: Surface Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 28
States / cities: Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more

Conditions: Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions: VP-102, Vehicle; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Saint Augustine, Florida • Plainfield, Indiana • Hunt Valley, Maryland + 3 more

Conditions: Idiopathic Eyelash Hypotrichosis
Interventions: bimatoprost formulation A solution, bimatoprost solution 0.03 %, vehicle of bimatoprost formulation A solution, vehicle of bimatoprost solution 0.03 %; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Healthy Volunteers
Interventions: rhNGF 20μg/mL, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Dry Eye Disease
Interventions: SI-614, Placebo; Drug
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more

Conditions: Plaque Psoriasis
Interventions: 188-0551 Solution, Vehicle Solution; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Sickle Cell Disease
Interventions: Aes-103, Placebo; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Keratoconjunctivitis Sicca
Interventions: Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution; Drug
Lead sponsor: Mitotech, SA; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye Disease
Interventions: 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Glendale, California • Torrance, California • Colorado Springs, Colorado + 19 more

Conditions: Erythematous Rosacea
Interventions: 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief, COL-118 facial gel vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Healthy Subjects
Interventions: AC-170 0.24%, AC-170 Vehicle; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Neurotrophic Keratopathy
Interventions: RGN-259, Placebo; Drug
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 29
States / cities: Laguna Hills, California • Loma Linda, California • Colorado Springs, Colorado + 25 more

Conditions: Dry Eye Disease
Interventions: AR-15512 Ophthalmic Solution, AR-15512 Ophthalmic Solution Vehicle; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 12 more

Conditions: Mesopic Vision, Night Vision Loss
Interventions: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo; Drug
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 25
States / cities: Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more

Conditions: Hypersensitivity, Immediate, Atopic Hypersensitivity
Interventions: Carbon Black, Diesel Exhaust Particles, Fine Concentrated Ambient Particles, Ultrafine Concentrated Ambient Particles, Saline; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Study of A-101 Topical Solution for the Treatment of Common Warts

Study of A-101 for the Treatment of Seborrheic Keratosis

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Study Evaluating the Safety and Efficacy of AR-15512

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

A Study to Compare the Effects of Different Sized Particles on Cells in the Nose